Drug Profile
XA 547
Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator BTG
- Class Antipsoriatics
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 12 Oct 1999 No-Development-Reported for Psoriasis in USA (Topical)